Organon, a global healthcare company, proudly announces the launch of RosuZet®, the 2-in-1 fixed dose combination therapy for lowering LDL cholesterol (LDL-C). RosuZet® combines two active ingredients, rosuvastatin and ezetimibe into a single pill, with complementary mode of action to inhibit cholesterol absorption and cholesterol biosynthesis, providing an effective treatment option that helps patients to attain LDL-C treatment goal.1 

The launch, strategically timed to coincide with World Heart Day, aims to raise awareness among Malaysians about the importance of monitoring their LDL-C levels.

Bilal Somra, the Executive Director and Founding Country Lead for Organon Malaysia, expressed the company’s enthusiasm in introducing RosuZet® as an innovative therapy shown to lower LDL-C levels more intensively compared to statin monotherapy, with a favourable safety profile.

“The launch of RosuZet® aligns with Organon’s mission to deliver impactful medicines for a healthy every day. We are excited to offer a treatment that is not only effective but also well-tolerated among patients struggling with the control of high LDL-C levels,” said Bilal. 

“Timing the launch of RosuZet® with World Heart Day serves as a reminder to all Malaysians, especially those aged 40 and above, to keep their LDL-C levels in check,” added Bilal.   

RosuZet® is available with a doctor’s prescription at your nearby GP clinics, hospitals and pharmacies. It is recommended to consult your physician for suitable treatment if you are suffered from hyperlipidemia.  

Twitter